Protein restriction for diabetic renal disease.
BACKGROUND
Diabetic renal disease (diabetic nephropathy) is a leading cause of end-stage renal failure. Once the process has started, it cannot be reversed by glycaemic control, but progression might be slowed by control of blood pressure and protein restriction.


OBJECTIVE
To assess the effects of dietary protein restriction on the progression of diabetic nephropathy in patients with diabetes.


METHODS
We searched The Cochrane Library, MEDLINE, EMBASE, ISI Proceedings, Science Citation Index Expanded and bibliographies of included studies.


METHODS
Randomised controlled trials (RCTs) and before and after studies of the effects of a modified or restricted protein diet on diabetic renal function in people with type 1 or type 2 diabetes following diet for at least four months were considered.


METHODS
Two reviewers performed data extraction and evaluation of quality independently. Pooling of results was done by means of random-effects model.


RESULTS
Twelve studies were included, nine RCTs and three before and after studies. Only one study explored all-cause mortality and end-stage renal disease (ESRD) as endpoints. The relative risk (RR) of ESRD or death was 0.23 (95% confidence interval (CI) 0.07 to 0.72) for patients assigned to a low protein diet (LPD). Pooling of the seven RCTs in patients with type 1 diabetes resulted in a non-significant reduction in the decline of glomerular filtration rate (GFR) of 0.1 ml/min/month (95% CI -0.1 to 0.3) in the LPD group. For type 2 diabetes, one trial showed a small insignificant improvement in the rate of decline of GFR in the protein-restricted group and a second found a similar decline in both the intervention and control groups. Actual protein intake in the intervention groups ranged from 0.7 to 1.1 g/kg/day. One study noted malnutrition in the LPD group. We found no data on the effects of LPDs on health-related quality of life and costs.


CONCLUSIONS
The results show that reducing protein intake appears to slightly slow progression to renal failure but not statistically significantly so. However, questions concerning the level of protein intake and compliance remain. Further longer-term research on large representative groups of patients with both type 1 and type 2 diabetes mellitus is necessary. Because of the variability amongst patients, there might perhaps be a six month therapeutic trial of protein restriction in all individuals, with continuation only in those who responded best. Trials are required of different types of protein.
Robertson
L
L
University of Aberdeen, Department of Public Health, Medical School, Polwarth Building, Foresterhill, Aberdeen, Scotland, UK, AB25 2ZD. l.robertson@abdn.ac.uk
Waugh
N
N
Robertson
A
A
D003928:Diabetic Nephropathies / Q000178:diet therapy*; D018753:Diet, Protein-Restricted; D004044:Dietary Proteins / Q000008:administration & dosage; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control
D004044:Dietary Proteins